kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”10.17802/2306-1278-2025-14-1-51-61kpccz-1499Research ArticleАНАЛИТИЧЕСКИЙ ОБЗОР. КардиологияREVIEW. CardiologyФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ У ПАЦИЕНТОВ ОТДЕЛЬНЫХ КЛИНИЧЕСКИХ ГРУПП: ОСОБЕННОСТИ ПАТОГЕНЕЗА И ВЛИЯНИЕ НА ТАКТИКУ КАТЕТЕРНОЙ АБЛАЦИИATRIAL FIBRILLATION IN PATIENTS OF CERTAIN CLINICAL GROUPS: FEATURES OF PATHOGENESIS AND IMPACT ON CATHETER ABLATION TACTICShttps://orcid.org/0000-0003-1300-4986ГоревМаксим ВасильевичGorevMaxim V.

врач по рентгенэндоваскулярным диагностике и лечению отделения рентгенохирургических методов диагностики и лечения государственного бюджетного учреждения здравоохранения «Городская клиническая больница № 52 Департамента здравоохранения города Москвы», Москва, Российская Федерация

Endovascular Image-guided Diagnostics and Treatment Specialist at the Department of Image-guided Surgical Methods of Diagnosis and Treatment, State Budgetary Healthcare Institution “Moscow City Clinical Hospital No.52”, Moscow, Russian Federation

drgorevmv@gmail.comhttps://orcid.org/0000-0002-4143-8899ФетцерДенис ВитальевичFetzerDenis V.

кандидат медицинских наук врач – сердечно-сосудистый хирург, заведующий отделением рентгенохирургических методов диагностики и лечения государственного бюджетного учреждения здравоохранения «Городская клиническая больница № 52 Департамента здравоохранения города Москвы», Москва, Российская Федерация

PhD, Cardiovascular Surgeon, Head of the Department of Image-guided Surgical Methods of Diagnosis and Treatment, State Budgetary Healthcare Institution “Moscow City Clinical Hospital No.52”, Moscow, Russian Federation

fettser@gmail.comhttps://orcid.org/0000-0002-0787-4347КовалевскаяЕлена АнатольевнаKovalevskayaElena A.

кандидат медицинских наук доцент кафедры общей терапии федерального государственного автономного образовательного учреждения высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации, Москва, Российская Федерация

PhD, Associate Professor at the Department of General Therapy, Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federatio

tolyaaa@mail.ruhttps://orcid.org/0000-0001-9803-2139ПотешкинаНаталия ГеоргиевнаPoteshkinaNatalia G.

доктор медицинских наук, профессор заведующая кафедрой общей терапии факультета дополнительного профессионального образования, руководитель университетской клиники федерального государственного автономного образовательного учреждения высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации, Москва, Российская Федерация

PhD, Head of the Department of General Therapy, Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation

nat-pa@yandex.ruhttps://orcid.org/0000-0003-4165-4599УразовскаяИрина ЛеонидовнаUrazovskayaIrina L.

кандидат медицинских наук ассистент кафедры федерального государственного бюджетного образовательного учреждения высшего образования «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Министерства здравоохранения Российской Федерации, Санкт-Петербург, Российская Федерация

PhD, Assistant Professor, Federal State Budgetary Educational Institution of Higher Education “North-Western State Medical University named after I.I. Mechnikov”, Saint Petersburg, Russian Federation

langelova@yandex.ruhttps://orcid.org/0000-0002-9880-516XСайгановСергей АнатольевичSayganovSergey A.

доктор медицинских наук, профессор ректор федерального государственного бюджетного образовательного учреждения высшего образования «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Министерства здравоохранения Российской Федерации, Санкт-Петербург, Российская Федерация

PhD, Professor, Rector, Federal State Budgetary Educational Institution of Higher Education “North-Western State Medical University named after I.I. Mechnikov”, Saint Petersburg, Russian Federation

sergey.sayganov@szgmu.ruГосударственное бюджетное учреждение здравоохранения «Городская клиническая больница № 52 Департамента здравоохранения города Москвы»РоссияState Budgetary Healthcare Institution “Moscow City Clinical Hospital No. 52”Russian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Healthcare of the Russian FederationRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education “North-Western State Medical University named after I.I. Mechnikov”Russian Federation2025280220251415161Copyright © Горев М.В., Фетцер Д.В., Ковалевская Е.А., Потешкина Н.Г., Уразовская И.Л., Сайганов С.А., 20252025Горев М.В., Фетцер Д.В., Ковалевская Е.А., Потешкина Н.Г., Уразовская И.Л., Сайганов С.А.Gorev M.V., Fetzer D.V., Kovalevskaya E.A., Poteshkina N.G., Urazovskaya I.L., Sayganov S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/1499Основные положения

Основные положения

Описаны механизмы развития идиопатической фибрилляции предсердий, фибрилляции предсердий в сочетании с артериальной гипертензией и ишемической болезнью сердца. В настоящее время тактика катетерного лечения фибрилляции предсердий основывается прежде всего на длительности приступов аритмии, а не на патофизиологических механизмах ее развития и прогрессирования. Подчеркнута необходимость патогенетического подхода к лечению нарушения ритма, являющегося наиболее распространенным в человеческой популяции.

 

 

Резюме

Резюме

Вероятность возникновения фибрилляции предсердий увеличивается с возрастом и в значительной степени зависит от выраженности сопутствующей кардиальной и экстракардиальной патологии. В настоящем обзоре проанализированы данные литературы о патогенезе и катетерном лечении фибрилляции предсердий у пациентов без видимой структурной и сердечно-сосудистой патологии (так называемая идиопатическая фибрилляция предсердий), лиц с артериальной гипертензией и ишемической болезнью сердца.

Highlights

Highlights

In this review the authors have described the mechanism of atrial fibrillation (AF) development in patients with different comorbidity – in idiopathic AF, the AF concomitant to atrial hypertension and AF concomitant to ischemic heart disease. Currently, the treatment tactics for AF are based primarily on the duration of arrhythmia episodes, and not on the pathophysiological mechanisms of its development and progression. In our work, we tried to draw attention to the need for a pathogenetic view on the most common heart rhythm disease.

 

 

Abstract

Abstract

The likelihood of atrial fibrillation occurrence increases with age and largely depends on the severity of concomitant cardiac and extracardiac pathology. In this review, we want to present an analysis of the data available in the literature on the pathogenesis and catheter treatment of atrial fibrillation in patients without visible structural and cardiovascular pathology (idiopathic atrial fibrillation), patients with hypertension and patients with coronary heart disease.

Фибрилляция предсердийМерцательная аритмияКатетерная аблацияКатетерная абляцияАртериальная гипертензияИшемическая болезнь сердцаИдиопатическаяAtrial fibrillationCatheter ablationCatheter ablationArterial hypertensionIschemic heart diseaseIdiopathic atrial fibrillationАвторы заявляют об отсутствии финансирования исследования.ReferencesHindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., Boriani G., Castella M., Dan G.A., Dilaveris P.E., et al. Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. .Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., Boriani G., Castella M., Dan G.A., Dilaveris P.E., et al. Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. .Potpara T.S., Stankovic G.R., Beleslin B.D., Polovina M.M., Marinkovic J.M., Ostojic M.C., Lip G.Y.H. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation. Implications of arrhythmia progression on prognosis: The Belgrade atrial fibrillation study. Chest. 2012;141(2):339–47. doi: 10.1378/chest.11-0340.Potpara T.S., Stankovic G.R., Beleslin B.D., Polovina M.M., Marinkovic J.M., Ostojic M.C., Lip G.Y.H. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation. Implications of arrhythmia progression on prognosis: The Belgrade atrial fibrillation study. Chest. 2012;141(2):339–47. doi: 10.1378/chest.11-0340.Chiang C.E., Naditch-Brûlé L., Murin J., Goethals M., Inoue H., O-Neill J., Silva-Cardoso J., Zharinov O., Gamra H., Alam S., Ponikowski P., Lewalter T., Rosenqvist M., Steg P.G. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythmia Electrophysiol. 2012;5(4):632–9. doi: 10.1161/CIRCEP.112.970749.Chiang C.E., Naditch-Brûlé L., Murin J., Goethals M., Inoue H., O-Neill J., Silva-Cardoso J., Zharinov O., Gamra H., Alam S., Ponikowski P., Lewalter T., Rosenqvist M., Steg P.G. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythmia Electrophysiol. 2012;5(4):632–9. doi: 10.1161/CIRCEP.112.970749.Wyse D.G., Van Gelder I.C., Ellinor P.T., Go A.S., Kalman J.M., Narayan S.M., Nattel S., Schotten U., Rienstra M. Lone atrial fibrillation: Does it exist? J Am Coll Cardiol. 2014;63(17):1715–23. doi: 10.1016/j.jacc.2014.01.023.Wyse D.G., Van Gelder I.C., Ellinor P.T., Go A.S., Kalman J.M., Narayan S.M., Nattel S., Schotten U., Rienstra M. Lone atrial fibrillation: Does it exist? J Am Coll Cardiol. 2014;63(17):1715–23. doi: 10.1016/j.jacc.2014.01.023.Wyse D.G., Van Gelder I.C., Ellinor P.T., Go A.S., Kalman J.M., Narayan S.M., Nattel S., Schotten U., Rienstra M. Lone atrial fibrillation: Does it exist? J Am Coll Cardiol. 2014;63(17):1715–23. doi: 10.1016/j.jacc.2014.01.023.Wyse D.G., Van Gelder I.C., Ellinor P.T., Go A.S., Kalman J.M., Narayan S.M., Nattel S., Schotten U., Rienstra M. Lone atrial fibrillation: Does it exist? J Am Coll Cardiol. 2014;63(17):1715–23. doi: 10.1016/j.jacc.2014.01.023.Haïssaguerre M., Jaïs P., Shah D.C., Takahashi .A., Hocini M., Quiniou G., Garrigue S., Le Mouroux A., Le Métayer P., Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–66. doi: 10.1056/NEJM199809033391003.Haïssaguerre M., Jaïs P., Shah D.C., Takahashi .A., Hocini M., Quiniou G., Garrigue S., Le Mouroux A., Le Métayer P., Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–66. doi: 10.1056/NEJM199809033391003.Scherlag B.J., Nakagawa H., Jackman W.M., Yamanashi W.S., Patterson E., Po S., Lazzara R. Electrical stimulation to identify neural elements on the heart: Their role in atrial fibrillation. J Interv Card Electrophysiol. 2005;13(SUPPL. 1):37–42. doi: 10.1007/s10840-005-2492-2.Scherlag B.J., Nakagawa H., Jackman W.M., Yamanashi W.S., Patterson E., Po S., Lazzara R. Electrical stimulation to identify neural elements on the heart: Their role in atrial fibrillation. J Interv Card Electrophysiol. 2005;13(SUPPL. 1):37–42. doi: 10.1007/s10840-005-2492-2.Zimmermann M., Adamec R., Metzger J. Atrial vulnerability in patients with paroxysmal “lone” atrial fibrillation. PACE - Pacing Clin Electrophysiol. 1998;21(10):1949–58. doi: 10.1111/j.1540-8159.1998.tb00015.x.Zimmermann M., Adamec R., Metzger J. Atrial vulnerability in patients with paroxysmal “lone” atrial fibrillation. PACE - Pacing Clin Electrophysiol. 1998;21(10):1949–58. doi: 10.1111/j.1540-8159.1998.tb00015.x.Teh A.W., Kistler P.M., Lee G., Medi C., Heck P.M., Spence S.J., Morton J.B., Sanders P., Kalman J.M. Long-term effects of catheter ablation for lone atrial fibrillation: Progressive atrial electroanatomic substrate remodeling despite successful ablation. Hear Rhythm. 2012;9(4):473–80. doi: 10.1016/j.hrthm.2011.11.013.Teh A.W., Kistler P.M., Lee G., Medi C., Heck P.M., Spence S.J., Morton J.B., Sanders P., Kalman J.M. Long-term effects of catheter ablation for lone atrial fibrillation: Progressive atrial electroanatomic substrate remodeling despite successful ablation. Hear Rhythm. 2012;9(4):473–80. doi: 10.1016/j.hrthm.2011.11.013.Husser D., Ueberham L., Hindricks G., Büttner P., Ingram C., Weeke P., Shoemaker M.B., Adams V., Arya A., Sommer P., Darbar D., Roden D.M., Bollmann A. Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillation. PLoS One. 2017;12(8):e0183690. doi: 10.1371/journal.pone.0183690.Husser D., Ueberham L., Hindricks G., Büttner P., Ingram C., Weeke P., Shoemaker M.B., Adams V., Arya A., Sommer P., Darbar D., Roden D.M., Bollmann A. Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillation. PLoS One. 2017;12(8):e0183690. doi: 10.1371/journal.pone.0183690.Batalov R.E., Khlynin M.S., Rogovskaya Y.V., Sazonova S.I., Tatarskiy R.B., Anfinogenova N.D., Popov S.V. Isolated Atrial Fibrillation, Inflammation and Efficacy of Radiofrequency Ablation: Preliminary Insights Based on a Single-Center Endomyocardial Biopsy Study. J Clin Med. 2023;12(4):1254. doi: 10.3390/jcm12041254.Batalov R.E., Khlynin M.S., Rogovskaya Y.V., Sazonova S.I., Tatarskiy R.B., Anfinogenova N.D., Popov S.V. Isolated Atrial Fibrillation, Inflammation and Efficacy of Radiofrequency Ablation: Preliminary Insights Based on a Single-Center Endomyocardial Biopsy Study. J Clin Med. 2023;12(4):1254. doi: 10.3390/jcm12041254.Fredersdorf S., Ücer E., Jungbauer C., Dornia C., Eglmeier J., Eissnert C., Hamer O.W., Weber S., Arzt M., von Bary C. Lone atrial fibrillation as a positive predictor of left atrial volume reduction following ablation of atrial fibrillation. Europace. 2014;16(1):26–32. doi: 10.1093/europace/eut152.Fredersdorf S., Ücer E., Jungbauer C., Dornia C., Eglmeier J., Eissnert C., Hamer O.W., Weber S., Arzt M., von Bary C. Lone atrial fibrillation as a positive predictor of left atrial volume reduction following ablation of atrial fibrillation. Europace. 2014;16(1):26–32. doi: 10.1093/europace/eut152.Ilyushenkova J., Sazonova S., Popov E., Zavadovsky K., Batalov R., Archakov E., Moskovskih T., Popov S., Minin S., Romanov A. Radiomic phenotype of epicardial adipose tissue in the prognosis of atrial fibrillation recurrence after catheter ablation in patients with lone atrial fibrillation. J Arrhythmia. 2022;38(5):682–93. doi: 10.1002/joa3.12760.Ilyushenkova J., Sazonova S., Popov E., Zavadovsky K., Batalov R., Archakov E., Moskovskih T., Popov S., Minin S., Romanov A. Radiomic phenotype of epicardial adipose tissue in the prognosis of atrial fibrillation recurrence after catheter ablation in patients with lone atrial fibrillation. J Arrhythmia. 2022;38(5):682–93. doi: 10.1002/joa3.12760.Ilyushenkova J.N., Sazonova S.I., Popov E.V., Batalov R.E., Minin S.M., Romanov A.B. Radiomic Phenotype of Periatrial Adipose Tissue in the Prognosis of Late Postablation Recurrence of Idiopathic Atrial Fibrillation. Sovremennye tehnologii v medicine. 2023;15(2):48–58. doi: 10.17691/stm2023.15.2.05.Ilyushenkova J.N., Sazonova S.I., Popov E.V., Batalov R.E., Minin S.M., Romanov A.B. Radiomic Phenotype of Periatrial Adipose Tissue in the Prognosis of Late Postablation Recurrence of Idiopathic Atrial Fibrillation. Sovremennye tehnologii v medicine. 2023;15(2):48–58. doi: 10.17691/stm2023.15.2.05.Ferreira M., Laranjo S., Cunha P., Geraldes V., Oliveira M., Rocha I. Orthostatic Stress and Baroreflex Sensitivity: A Window into Autonomic Dysfunction in Lone Paroxysmal Atrial Fibrillation. J Clin Med. 2023;12(18):5857. doi: 10.3390/jcm12185857.Ferreira M., Laranjo S., Cunha P., Geraldes V., Oliveira M., Rocha I. Orthostatic Stress and Baroreflex Sensitivity: A Window into Autonomic Dysfunction in Lone Paroxysmal Atrial Fibrillation. J Clin Med. 2023;12(18):5857. doi: 10.3390/jcm12185857.Efremidis M., Letsas K.P., Lioni L., Deftereos S., Giannopoulos G., Kossyvakis C., Tsikrikas S., Charalampous C., Kollias G., Xydonas S., Synetos A., Sideris A., Toutouzas K., Stefanadis C. The impact of vagotonic, adrenergic, and random type of paroxysmal atrial fibrillation on left atrial ablation outcomes. Int J Cardiol. 2013;168(4):4015–8. doi: 10.1016/j.ijcard.2013.06.075.Efremidis M., Letsas K.P., Lioni L., Deftereos S., Giannopoulos G., Kossyvakis C., Tsikrikas S., Charalampous C., Kollias G., Xydonas S., Synetos A., Sideris A., Toutouzas K., Stefanadis C. The impact of vagotonic, adrenergic, and random type of paroxysmal atrial fibrillation on left atrial ablation outcomes. Int J Cardiol. 2013;168(4):4015–8. doi: 10.1016/j.ijcard.2013.06.075.Zhou Q., Cao H., Xu Z., Lan R., Chen X., Wang D., Xu W. Baseline serum globulin as a predictor of the recurrence of lone atrial fibrillation after radiofrequency catheter ablation. Anatol J Cardiol. 2017;17(5):381–5. doi: 10.14744/AnatolJCardiol.2016.7393.Zhou Q., Cao H., Xu Z., Lan R., Chen X., Wang D., Xu W. Baseline serum globulin as a predictor of the recurrence of lone atrial fibrillation after radiofrequency catheter ablation. Anatol J Cardiol. 2017;17(5):381–5. doi: 10.14744/AnatolJCardiol.2016.7393.Cao H., Xu W., Chen X., Zhou Q., Lan R., Chen Y., Wang D. Functional promoter −1816C>G variant of RANKL predicts risk and prognosis of lone atrial fibrillation. Heart Vessels. 2019;34(1):151–8. doi: 10.1007/s00380-018-1222-5.Cao H., Xu W., Chen X., Zhou Q., Lan R., Chen Y., Wang D. Functional promoter −1816C>G variant of RANKL predicts risk and prognosis of lone atrial fibrillation. Heart Vessels. 2019;34(1):151–8. doi: 10.1007/s00380-018-1222-5.Li N., Feng Q., Yu F., Zhou J., Guo X. Plasma growth differentiation factor-15 in patients with “lone” atrial fibrillation. J Clin Lab Anal. 2022;36(5):1–7. doi: 10.1002/jcla.24373.Li N., Feng Q., Yu F., Zhou J., Guo X. Plasma growth differentiation factor-15 in patients with “lone” atrial fibrillation. J Clin Lab Anal. 2022;36(5):1–7. doi: 10.1002/jcla.24373.Shen Y, Ma G, Sun M, Li M, Chen M. Low plasma renin activity is associated with “Apparently” idiopathic atrial fibrillation. IJC Hear Vasc. 2023;49:101286. doi: 10.1016/j.ijcha.2023.101286.Shen Y, Ma G, Sun M, Li M, Chen M. Low plasma renin activity is associated with “Apparently” idiopathic atrial fibrillation. IJC Hear Vasc. 2023;49:101286. doi: 10.1016/j.ijcha.2023.101286.Galenko O., Jacobs V., Knight S., Taylor M., Cutler M.J., Muhlestein J.B., Carlquist J.L., Knowlton K.U., Jared Bunch T. The role of microRNAs in the development, regulation, and treatment of atrial fibrillation. J Interv Card Electrophysiol. 2019;55(3):297–305. doi: 10.1007/s10840-018-0495-z.Galenko O., Jacobs V., Knight S., Taylor M., Cutler M.J., Muhlestein J.B., Carlquist J.L., Knowlton K.U., Jared Bunch T. The role of microRNAs in the development, regulation, and treatment of atrial fibrillation. J Interv Card Electrophysiol. 2019;55(3):297–305. doi: 10.1007/s10840-018-0495-z.Canpolat U., Aytemir K., Hazirolan T., Özer N., Oto A. Relationship between vitamin D level and left atrial fibrosis in patients with lone paroxysmal atrial fibrillation undergoing cryoballoon-based catheter ablation. J Cardiol. 2017;69(1):16–23. doi: 10.1016/j.jjcc.2016.06.012.Canpolat U., Aytemir K., Hazirolan T., Özer N., Oto A. Relationship between vitamin D level and left atrial fibrosis in patients with lone paroxysmal atrial fibrillation undergoing cryoballoon-based catheter ablation. J Cardiol. 2017;69(1):16–23. doi: 10.1016/j.jjcc.2016.06.012.Wijesurendra R.S., Liu A., Eichhorn C., Ariga R., Levelt E., Clarke W.T., Rodgers C.T., Karamitsos T.D., Bashir Y., Ginks M., Rajappan K., Betts T., Ferreira V.M., Neubauer S., Casadei B. Lone Atrial Fibrillation Is Associated With Impaired Left Ventricular Energetics That Persists Despite Successful Catheter Ablation. Circulation. 2016;134(15):1068-1081. doi: 10.1161/CIRCULATIONAHA.116.022931.Wijesurendra R.S., Liu A., Eichhorn C., Ariga R., Levelt E., Clarke W.T., Rodgers C.T., Karamitsos T.D., Bashir Y., Ginks M., Rajappan K., Betts T., Ferreira V.M., Neubauer S., Casadei B. Lone Atrial Fibrillation Is Associated With Impaired Left Ventricular Energetics That Persists Despite Successful Catheter Ablation. Circulation. 2016;134(15):1068-1081. doi: 10.1161/CIRCULATIONAHA.116.022931.Миронова Е.С., Миронов Н.Ю., Миронова Н.А., Новиков П.С., Новиков И.А., Лайович Л.Ю., Майков Е.Б., Голицын С.П. Электрофизиологические параметры сердца и результаты противоаритмического лечения у больных с пароксизмальной формой фибрилляции предсердий, идиопатической и в сочетании с гипертонической болезнью. Кардиология. 2019;59(8):39-46. doi: 10.18087/cardio.2019.8.n644.Mironova E.S., Mironov N.Y., Mironova N.A., Novikov P.S., Novikov I.A., Layovich L.Y., Maykov E.B., Golitsyn S.P. Electrophysiological cardiac parameters and results of antiarrhythmic treatment in patients with paroxysmal atrial fibrillation (lone and associated with arterial hypertension). Kardiologiya. 2019;59(8):39–46. doi: 10.18087/cardio.2019.8.n644. (In Russian)Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, Incidence, Prognosis, and Predisposing Conditions for Atrial Fibrillation: Population-Based Estimates. Am J Cardiol. 1998;82(7 A):2N-9N. doi: 10.1016/s0002-9149(98)00583-9.Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, Incidence, Prognosis, and Predisposing Conditions for Atrial Fibrillation: Population-Based Estimates. Am J Cardiol. 1998;82(7 A):2N-9N. doi: 10.1016/s0002-9149(98)00583-9.Dzeshka M.S., Shantsila A., Shantsila E., Lip G.Y.H. Atrial Fibrillation and Hypertension. Hypertension. 2017;70(5):854–61. doi: 10.1161/HYPERTENSIONAHA.117.08934.Dzeshka M.S., Shantsila A., Shantsila E., Lip G.Y.H. Atrial Fibrillation and Hypertension. Hypertension. 2017;70(5):854–61. doi: 10.1161/HYPERTENSIONAHA.117.08934.Gorenek B, Pelliccia A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, e Van Gelder IC, Halle M, Kudaiberdieva G, Lane DAt al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2017;19(2):190–225. doi: 10.1093/europace/euw242.Gorenek B, Pelliccia A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, e Van Gelder IC, Halle M, Kudaiberdieva G, Lane DAt al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2017;19(2):190–225. doi: 10.1093/europace/euw242.Allan V., Honarbakhsh S., Casas J.P., Wallace J., Hunter R., Schilling R., Perel P., Morley K., Banerjee A., Hemingway H. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation?: A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017;117(5):837–50. doi: 10.1160/TH16-11-0825.Allan V., Honarbakhsh S., Casas J.P., Wallace J., Hunter R., Schilling R., Perel P., Morley K., Banerjee A., Hemingway H. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation?: A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017;117(5):837–50. doi: 10.1160/TH16-11-0825.Ikejder Y., Sebbani M., Hendy I., Khramz M., Khatouri A., Bendriss L. Impact of Arterial Hypertension on Left Atrial Size and Function. Biomed Res Int. 2020;2020:2587530. doi: 10.1155/2020/2587530.Ikejder Y., Sebbani M., Hendy I., Khramz M., Khatouri A., Bendriss L. Impact of Arterial Hypertension on Left Atrial Size and Function. Biomed Res Int. 2020;2020:2587530. doi: 10.1155/2020/2587530.Verdecchia P., Reboldi G.P., Gattobigio R., Bentivoglio M., Borgioni C., Angeli F., Carluccio E., Sardone M.G., Porcellati C.Atrial fibrillation in hypertension: Predictors and outcome. Hypertension. 2003;41(2):218–23. doi: 10.1161/01.hyp.0000052830.02773.e4.Verdecchia P., Reboldi G.P., Gattobigio R., Bentivoglio M., Borgioni C., Angeli F., Carluccio E., Sardone M.G., Porcellati C.Atrial fibrillation in hypertension: Predictors and outcome. Hypertension. 2003;41(2):218–23. doi: 10.1161/01.hyp.0000052830.02773.e4.Larstorp A.C.K., Stokke I.M., Kjeldsen S.E., Hecht Olsen M., Okin P.M., Devereux R.B., Wachtell K. Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. Blood Press. 2019;28(5):317–26. doi: 10.1080/08037051.2019.1633905.Larstorp A.C.K., Stokke I.M., Kjeldsen S.E., Hecht Olsen M., Okin P.M., Devereux R.B., Wachtell K. Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. Blood Press. 2019;28(5):317–26. doi: 10.1080/08037051.2019.1633905.Okin P.M., Hille D.A., Larstorp A.C.K., Wachtell K., Kjeldsen S.E., Dahlöf B., Devereux R.B. Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients. Hypertension. 2015;66(2):368–73. doi: 10.1161/HYPERTENSIONAHA.115.05728.Okin P.M., Hille D.A., Larstorp A.C.K., Wachtell K., Kjeldsen S.E., Dahlöf B., Devereux R.B. Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients. Hypertension. 2015;66(2):368–73. doi: 10.1161/HYPERTENSIONAHA.115.05728.Galzerano D., Di Michele S., Paolisso G., Tuccillo B., Lama D., Carbotta S., Cittadini A., Tedesco M.A., Gaudio C. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. JRAAS - J Renin-Angiotensin-Aldosterone Syst. 2012;13(4):496–503. doi: 10.1177/1470320312443909.Galzerano D., Di Michele S., Paolisso G., Tuccillo B., Lama D., Carbotta S., Cittadini A., Tedesco M.A., Gaudio C. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. JRAAS - J Renin-Angiotensin-Aldosterone Syst. 2012;13(4):496–503. doi: 10.1177/1470320312443909.Zhao Z., Yang Y., Wang J., Dong Z., Niu X., Liu E., Liu T., Li L., Liang Y., Li G. Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension: A clinical trial. Clin Cardiol. 2020;43(12):1592–600. doi: 10.1002/clc.23487.Zhao Z., Yang Y., Wang J., Dong Z., Niu X., Liu E., Liu T., Li L., Liang Y., Li G. Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension: A clinical trial. Clin Cardiol. 2020;43(12):1592–600. doi: 10.1002/clc.23487.Okin P.M., Wachtell K., Kjeldsen S.E., Julius S., Lindholm L.H., Dahlöf B., Hille D.A., Nieminen M.S., Edelman J.M., Devereux R.B. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol. 2008;1(5):337–43. doi: 10.1161/CIRCEP.108.795351.Okin P.M., Wachtell K., Kjeldsen S.E., Julius S., Lindholm L.H., Dahlöf B., Hille D.A., Nieminen M.S., Edelman J.M., Devereux R.B. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol. 2008;1(5):337–43. doi: 10.1161/CIRCEP.108.795351.Steinberg J.S., Blount N., Ponomarev D., Shabanov V., Pokushalov E., Romanov A. The Evaluate Renal Artery Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation (ERADICATE-AF) trial: arrhythmia suppression, blood pressure control, and potential interactions. Europace. 2023;25(5): euad107. doi: 10.1093/europace/euad107.Steinberg J.S., Blount N., Ponomarev D., Shabanov V., Pokushalov E., Romanov A. The Evaluate Renal Artery Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation (ERADICATE-AF) trial: arrhythmia suppression, blood pressure control, and potential interactions. Europace. 2023;25(5): euad107. doi: 10.1093/europace/euad107.Giannopoulos G., Kossyvakis C., Efremidis M., Katsivas A., Panagopoulou V., Doudoumis K., Raisakis K., Letsas K., Rentoukas I., Pyrgakis V., Manolis A.S., Tousoulis D., Stefanadis C., Deftereos S. Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: A randomized, controlled study. Circulation. 2014;130(16):1346–52. doi: 10.1161/CIRCULATIONAHA.114.010999.Giannopoulos G., Kossyvakis C., Efremidis M., Katsivas A., Panagopoulou V., Doudoumis K., Raisakis K., Letsas K., Rentoukas I., Pyrgakis V., Manolis A.S., Tousoulis D., Stefanadis C., Deftereos S. Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: A randomized, controlled study. Circulation. 2014;130(16):1346–52. doi: 10.1161/CIRCULATIONAHA.114.010999.Giannopoulos G., Kossyvakis C., Angelidis C., Efremidis M., Panagopoulou V., Letsas K., Bouras G., Vassilikos V.P., Goudevenos J., Tousoulis D., Lekakis J., Deftereos S. Amino-terminal B-natriuretic peptide levels and postablation recurrence in hypertensive patients with paroxysmal atrial fibrillation. Hear Rhythm [Internet]. 2015;12(7):1470–5. doi: 10.1016/j.hrthm.2015.04.002.Giannopoulos G., Kossyvakis C., Angelidis C., Efremidis M., Panagopoulou V., Letsas K., Bouras G., Vassilikos V.P., Goudevenos J., Tousoulis D., Lekakis J., Deftereos S. Amino-terminal B-natriuretic peptide levels and postablation recurrence in hypertensive patients with paroxysmal atrial fibrillation. Hear Rhythm [Internet]. 2015;12(7):1470–5. doi: 10.1016/j.hrthm.2015.04.002.Winkle R.A., Jarman J.W.E., Mead R.H., Engel G., Kong M.H., Fleming W., Patrawala R.A. Predicting atrial fibrillation ablation outcome: The CAAP-AF score. Hear Rhythm. 2016;13(11):2119–25. doi: 10.1016/j.hrthm.2016.07.018.Winkle R.A., Jarman J.W.E., Mead R.H., Engel G., Kong M.H., Fleming W., Patrawala R.A. Predicting atrial fibrillation ablation outcome: The CAAP-AF score. Hear Rhythm. 2016;13(11):2119–25. doi: 10.1016/j.hrthm.2016.07.018.Michniewicz E., Mlodawska E., Lopatowska P., Tomaszuk-Kazberuk A., Malyszko J. Patients with atrial fibrillation and coronary artery disease – Double trouble. Adv Med Sci. 2018;63(1):30–5. doi: 10.1016/j.advms.2017.06.005.Michniewicz E., Mlodawska E., Lopatowska P., Tomaszuk-Kazberuk A., Malyszko J. Patients with atrial fibrillation and coronary artery disease – Double trouble. Adv Med Sci. 2018;63(1):30–5. doi: 10.1016/j.advms.2017.06.005.Байракова Ю.В., Понасенко А.В., Хуторная М.В., Кузьмина А.А., Казачек Я.В., Барбараш О.Л. Роль полиморфизмов гена СRP в возникновении фибрилляции предсердий у пациентов ИБС. Комплексные проблемы сердечно-сосудистых заболеваний. 2017;(3):37-46. doi:10.17802/2306-1278-2017-6-3-37-46Bayrakova Yu.V., Ponasenko A.V., Khutornaya M. V., Kuzmina A.A., Kazachek Yu.V., Barbarash O.L. The role of polymorphisms of crp gene in occurrence of atrial fibrilation in cad patients. Complex Issues Cardiovasc Dis [Internet]. 2017 Jan 1;(3):37–46. doi:10.17802/2306-1278-2017-6-3-37-46 (In Russian)Kornej J., Hindricks G., Arya A., Sommer P., Husser D., Rolf S., Bollmann A. Presence and extent of coronary artery disease as predictor for AF recurrences after catheter ablation: The Leipzig Heart Center AF Ablation Registry. Int J Cardiol. 2015;181:188–92. doi: 10.1016/j.ijcard.2014.12.039.Kornej J., Hindricks G., Arya A., Sommer P., Husser D., Rolf S., Bollmann A. Presence and extent of coronary artery disease as predictor for AF recurrences after catheter ablation: The Leipzig Heart Center AF Ablation Registry. Int J Cardiol. 2015;181:188–92. doi: 10.1016/j.ijcard.2014.12.039.Liu L., Zhao D., Zhang J., Yang H., Abdu F.A., Guo R., Li S., Tang K., Li H., Che W., Xu Y. Impact of Stable Coronary Artery Disease on the Efficacy of Cryoballoon Ablation for the Atrial Fibrillation. Am J Med Sci]. 2019;358(3):204–11. doi: 10.1016/j.amjms.2019.06.004.Liu L., Zhao D., Zhang J., Yang H., Abdu F.A., Guo R., Li S., Tang K., Li H., Che W., Xu Y. Impact of Stable Coronary Artery Disease on the Efficacy of Cryoballoon Ablation for the Atrial Fibrillation. Am J Med Sci]. 2019;358(3):204–11. doi: 10.1016/j.amjms.2019.06.004.Winkle R.A., Mead R.H., Engel G., Patrawala R.A. Long-term results of atrial fibrillation ablation: The importance of all initial ablation failures undergoing a repeat ablation. Am Heart J. 2011;162(1):193–200. doi: 10.1016/j.ahj.2011.04.013.Winkle R.A., Mead R.H., Engel G., Patrawala R.A. Long-term results of atrial fibrillation ablation: The importance of all initial ablation failures undergoing a repeat ablation. Am Heart J. 2011;162(1):193–200. doi: 10.1016/j.ahj.2011.04.013.Marrouche N.F., Wilber D., Hindricks G., Jais P., Akoum N., Marchlinski F., Kholmovski E., Burgon N., Hu N., Mont L. et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: The DECAAF study. JAMA - J Am Med Assoc. 2014;311(5):498–506. doi: 10.1001/jama.2014.3.Marrouche N.F., Wilber D., Hindricks G., Jais P., Akoum N., Marchlinski F., Kholmovski E., Burgon N., Hu N., Mont L. et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: The DECAAF study. JAMA - J Am Med Assoc. 2014;311(5):498–506. doi: 10.1001/jama.2014.3.Oakes R.S., Badger T.J., Kholmovski E.G., Akoum N., Burgon N.S., Fish E.N., Blauer J.J., Rao S.N., DiBella E.V., Segerson N.M., Daccarett M., Windfelder J., McGann C.J., Parker D., MacLeod R.S., Marrouche N.F. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009;119(13):1758–67. doi: 10.1161/CIRCULATIONAHA.108.811877.Oakes R.S., Badger T.J., Kholmovski E.G., Akoum N., Burgon N.S., Fish E.N., Blauer J.J., Rao S.N., DiBella E.V., Segerson N.M., Daccarett M., Windfelder J., McGann C.J., Parker D., MacLeod R.S., Marrouche N.F. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009;119(13):1758–67. doi: 10.1161/CIRCULATIONAHA.108.811877.Hiraya D., Sato A., Hoshi T., Watabe H., Yoshida K., Komatsu Y., Sekiguchi Y., Nogami A., Ieda M., Aonuma K.. Impact of coronary artery disease and revascularization on recurrence of atrial fibrillation after catheter ablation: Importance of ischemia in managing atrial fibrillation. J Cardiovasc Electrophysiol. 2019;30(9):1491–8. doi: 10.1111/jce.14029.Hiraya D., Sato A., Hoshi T., Watabe H., Yoshida K., Komatsu Y., Sekiguchi Y., Nogami A., Ieda M., Aonuma K.. Impact of coronary artery disease and revascularization on recurrence of atrial fibrillation after catheter ablation: Importance of ischemia in managing atrial fibrillation. J Cardiovasc Electrophysiol. 2019;30(9):1491–8. doi: 10.1111/jce.14029.Packer D.L., Mark D.B., Robb R.A., Monahan K.H., Bahnson T.D., Poole J.E., Noseworthy P.A., Rosenberg Y.D., Jeffries N., Mitchell L.B. et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest among Patients with Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA - J Am Med Assoc. 2019;321(13):1261–74. doi: 10.1001/jama.2019.0693.Packer D.L., Mark D.B., Robb R.A., Monahan K.H., Bahnson T.D., Poole J.E., Noseworthy P.A., Rosenberg Y.D., Jeffries N., Mitchell L.B. et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest among Patients with Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA - J Am Med Assoc. 2019;321(13):1261–74. doi: 10.1001/jama.2019.0693.Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., Голицын С.П., Голухова Е.З., Горев М.В., Давтян К.В., Драпкина О.М., Кропачева Е.С., Кучинская Е.А. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/1560-4071-2021-4594Arakelyan M.G., Bockeria L.A., Vasilieva E.Y., Golitsyn S.P., Golukhova E.Z., Gorev M.V., Davtyan K.V., Drapkina O.M., Kropacheva E.S., Kuchinskaya E.A. et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russ J Cardiol. 20218;26(7):4594. doi:10.15829/1560-4071-2021-4594 (In Russian)Verma A., Jiang C., Betts T.R., Chen J., Deisenhofer I., Mantovan R., Macle L., Morillo C.A., Haverkamp W., Weerasooriya R., Albenque J.P., Nardi S., Menardi E., Novak P., Sanders P.; STAR AF II Investigators. Approaches to Catheter Ablation for Persistent Atrial Fibrillation. N Engl J Med. 2015;372(19):1812–22.Verma A., Jiang C., Betts T.R., Chen J., Deisenhofer I., Mantovan R., Macle L., Morillo C.A., Haverkamp W., Weerasooriya R., Albenque J.P., Nardi S., Menardi E., Novak P., Sanders P.; STAR AF II Investigators. Approaches to Catheter Ablation for Persistent Atrial Fibrillation. N Engl J Med. 2015;372(19):1812–22.Balaji S., Kron J., Stecker E.C. Catheter Ablation of Recurrent Lone Atrial Fibrillation in Teenagers with a Structurally Normal Heart. Pacing Clin Electrophysiol. 2016;39(1):60–4. doi: 10.1111/pace.12774.Balaji S., Kron J., Stecker E.C. Catheter Ablation of Recurrent Lone Atrial Fibrillation in Teenagers with a Structurally Normal Heart. Pacing Clin Electrophysiol. 2016;39(1):60–4. doi: 10.1111/pace.12774.Parlavecchio A., Vetta G., Coluccia G., Pistelli L., Caminiti R., Ajello M., Magnocavallo M., Dattilo G., Foti R., Carerj S., Crea P., Accogli M., Chierchia G.B., de Asmundis C., Della Rocca D.G., Palmisano P. Catheter ablation in patients with paroxysmal atrial fibrillation and absence of structural heart disease: A meta-analysis of randomized trials. IJC Hear Vasc. 2023;49:101292. doi: 10.1016/j.ijcha.2023.101292.Parlavecchio A., Vetta G., Coluccia G., Pistelli L., Caminiti R., Ajello M., Magnocavallo M., Dattilo G., Foti R., Carerj S., Crea P., Accogli M., Chierchia G.B., de Asmundis C., Della Rocca D.G., Palmisano P. Catheter ablation in patients with paroxysmal atrial fibrillation and absence of structural heart disease: A meta-analysis of randomized trials. IJC Hear Vasc. 2023;49:101292. doi: 10.1016/j.ijcha.2023.101292.Furst M.L., Saarel E.V., Hussein A.A., Wazni .O.M., Tchou P., Kanj M., Saliba W.I., Aziz P.F. Medical and Interventional Outcomes in Pediatric Lone Atrial Fibrillation. JACC Clin Electrophysiol. 2018;4(5):638–48. doi: 10.1016/j.jacep.2018.02.014.Furst M.L., Saarel E.V., Hussein A.A., Wazni .O.M., Tchou P., Kanj M., Saliba W.I., Aziz P.F. Medical and Interventional Outcomes in Pediatric Lone Atrial Fibrillation. JACC Clin Electrophysiol. 2018;4(5):638–48. doi: 10.1016/j.jacep.2018.02.014.El Assaad I., Hammond B.H., Kost L.D., Worley S., Janson C.M., Sherwin E.D., Stephenson E.A., Johnsrude C.L., Niu M., Shetty I., Lawrence D., McCanta A.C., Balaji S., Sanatani S., Fish F., Webster G., Aziz P.F. Management and outcomes of atrial fibrillation in 241 healthy children and young adults: Revisiting “lone” atrial fibrillation—A multi-institutional PACES collaborative study. Hear Rhythm. 2021;18(11):1815–22. doi: 10.1016/j.hrthm.2021.07.066.El Assaad I., Hammond B.H., Kost L.D., Worley S., Janson C.M., Sherwin E.D., Stephenson E.A., Johnsrude C.L., Niu M., Shetty I., Lawrence D., McCanta A.C., Balaji S., Sanatani S., Fish F., Webster G., Aziz P.F. Management and outcomes of atrial fibrillation in 241 healthy children and young adults: Revisiting “lone” atrial fibrillation—A multi-institutional PACES collaborative study. Hear Rhythm. 2021;18(11):1815–22. doi: 10.1016/j.hrthm.2021.07.066.Хидирова Л.Д., Яхонтов Д.А., Зенин С.А. Особенности течения фибрилляции предсердий у пациентов с коморбидностью в зависимости от проводимой терапии. Комплексные проблемы сердечно-сосудистых заболеваний. 2019;8(2):21-29. doi:10.17802/2306-1278-2019-8-2-21-29Khidirova L.D., Yakhontov D.A., Zenin S.A. Atrial fibrillation in comorbid patients depending on the treatment regimen. Complex Issues of Cardiovascular Diseases. 2019;8(2):21–9. doi:10.17802/2306-1278-2019-8-2-21-29 (In Russian)Pison L., Hocini M., Potpara T.S., Todd D., Chen J., Blomstrom-Lundqvist C.; Scientific Initiative Committee, European Heart Rhythm Association. Work-up and management of lone atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace. 2014;16(10):1521–3. doi: 10.1093/europace/euu277.Pison L., Hocini M., Potpara T.S., Todd D., Chen J., Blomstrom-Lundqvist C.; Scientific Initiative Committee, European Heart Rhythm Association. Work-up and management of lone atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace. 2014;16(10):1521–3. doi: 10.1093/europace/euu277.Aryana A., Baker J.H., Espinosa Ginic M.A., Pujara D.K., Bowers M.R., O’Neill P.G., Ellenbogen K.A., Di Biase L., d'Avila A., Natale A. Posterior wall isolation using the cryoballoon in conjunction with pulmonary vein ablation is superior to pulmonary vein isolation alone in patients with persistent atrial fibrillation: A multicenter experience. Hear Rhythm. 2018;15(8):1121–9. doi: 10.1016/j.hrthm.2018.05.014.Aryana A., Baker J.H., Espinosa Ginic M.A., Pujara D.K., Bowers M.R., O’Neill P.G., Ellenbogen K.A., Di Biase L., d'Avila A., Natale A. Posterior wall isolation using the cryoballoon in conjunction with pulmonary vein ablation is superior to pulmonary vein isolation alone in patients with persistent atrial fibrillation: A multicenter experience. Hear Rhythm. 2018;15(8):1121–9. doi: 10.1016/j.hrthm.2018.05.014.Buiatti A., Kaess B., Reents T., Semmler V., Telishveska M., Bourier F., Kornmayer M., Kottmaier M., Hessling G., Deisenhofer I. Catheter Ablation for “Lone” Atrial Fibrillation: Efficacy and Predictors of Recurrence. J Cardiovasc Electrophysiol. 2016;27(5):536–41. doi: 10.1111/jce.12936.Buiatti A., Kaess B., Reents T., Semmler V., Telishveska M., Bourier F., Kornmayer M., Kottmaier M., Hessling G., Deisenhofer I. Catheter Ablation for “Lone” Atrial Fibrillation: Efficacy and Predictors of Recurrence. J Cardiovasc Electrophysiol. 2016;27(5):536–41. doi: 10.1111/jce.12936.Горев М.В., Уразовская И.Л., Сайганов С.А. Интраоперационные изменения предсердного ритма при катетерной аблации фибрилляции предсердий у пациентов с артериальной гипертензией и ишемической болезнью сердца. Сибирский журнал клинической и экспериментальной медицины. 2023;38(4):167-175. doi:10.29001/2073-8552-2023-38-4-167-175Gorev M.V., Urazovskaya I.L., Sayganov S.A. Intraoperative atrial rhythm changes during atrial fibrillation catheter ablation in patients with arterial hypertension and coronary artery disease. Sib J Clin Exp Med. 2024;38(4):167–75. A doi:10.29001/2073-8552-2023-38-4-167-175 (In Russian)Sato T., Sotomi Y., Hikoso S., Nakatani D., Mizuno H., Okada K., Dohi T., Kitamura T., Sunaga A., Kida H. et al. DR-FLASH Score Is Useful for Identifying Patients With Persistent Atrial Fibrillation Who Require Extensive Catheter Ablation Procedures. J Am Heart Assoc. 2022;11(16). doi: 10.1161/JAHA.121.024916.Sato T., Sotomi Y., Hikoso S., Nakatani D., Mizuno H., Okada K., Dohi T., Kitamura T., Sunaga A., Kida H. et al. DR-FLASH Score Is Useful for Identifying Patients With Persistent Atrial Fibrillation Who Require Extensive Catheter Ablation Procedures. J Am Heart Assoc. 2022;11(16). doi: 10.1161/JAHA.121.024916.Chen J., Wang H., Zhou M., Zhao L. Catheter ablation for lone atrial fibrillation in individuals aged under 35 years. 2019; 29(5):643-648. doi: 10.1017/S1047951119000416.Chen J., Wang H., Zhou M., Zhao L. Catheter ablation for lone atrial fibrillation in individuals aged under 35 years. 2019; 29(5):643-648. doi: 10.1017/S1047951119000416.Pison L., Gelsomino S., Lucà F., Parise O., Maessen J.G., Crijns H.J., La Meir M. Effectiveness and safety of simultaneous hybrid thoracoscopic and endocardial catheter ablation of lone atrial fibrillation. 2014;3(1):38–44. doi: 10.3978/j.issn.2225-319X.2013.12.10.Pison L., Gelsomino S., Lucà F., Parise O., Maessen J.G., Crijns H.J., La Meir M. Effectiveness and safety of simultaneous hybrid thoracoscopic and endocardial catheter ablation of lone atrial fibrillation. 2014;3(1):38–44. doi: 10.3978/j.issn.2225-319X.2013.12.10.Qin M., Liu X., Jiang W., Wu S., Zhang X., Po S. Vagal response during pulmonary vein isolation: Re-recognized its characteristics and implications in lone paroxysmal atrial fibrillation. Int J Cardiol. 2016;211:7–13. doi: 10.1016/j.ijcard.2016.02.116.Qin M., Liu X., Jiang W., Wu S., Zhang X., Po S. Vagal response during pulmonary vein isolation: Re-recognized its characteristics and implications in lone paroxysmal atrial fibrillation. Int J Cardiol. 2016;211:7–13. doi: 10.1016/j.ijcard.2016.02.116.Steinberg J.S., Shabanov V., Ponomarev D., Losik D., Ivanickiy E., Kropotkin E., Polyakov K., Ptaszynski P., Keweloh B., Yao C.J., Pokushalov E.A., Romanov A.B. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence among Patients with Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA - J Am Med Assoc. 2020;323(3):248–55. doi: 10.1001/jama.2019.21187.Steinberg J.S., Shabanov V., Ponomarev D., Losik D., Ivanickiy E., Kropotkin E., Polyakov K., Ptaszynski P., Keweloh B., Yao C.J., Pokushalov E.A., Romanov A.B. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence among Patients with Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA - J Am Med Assoc. 2020;323(3):248–55. doi: 10.1001/jama.2019.21187.Heradien M., Mahfoud F., Greyling C., Lauder L., van der Bijl P., Hettrick D.A., Stilwaney W., Sibeko S., Jansen van Rensburg R., Peterson D., Khwinani B., Goosen A., Saaiman J.A., Ukena C., Böhm M., Brink P.A. Renal denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: Randomized, sham-controlled trial. Hear Rhythm. 2022;19(11):1765–73. doi: 10.1016/j.hrthm.2022.06.031.Heradien M., Mahfoud F., Greyling C., Lauder L., van der Bijl P., Hettrick D.A., Stilwaney W., Sibeko S., Jansen van Rensburg R., Peterson D., Khwinani B., Goosen A., Saaiman J.A., Ukena C., Böhm M., Brink P.A. Renal denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: Randomized, sham-controlled trial. Hear Rhythm. 2022;19(11):1765–73. doi: 10.1016/j.hrthm.2022.06.031.Kiuchi M.G., Chen S., Hoye N.A., Pürerfellner H. Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. J Interv Card Electrophysiol. 2018;51(1):51–9. doi: 10.1007/s10840-017-0302-2.Kiuchi M.G., Chen S., Hoye N.A., Pürerfellner H. Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. J Interv Card Electrophysiol. 2018;51(1):51–9. doi: 10.1007/s10840-017-0302-2.Kirstein B., Tomala J., Mayer J., Ulbrich S., Wagner M., Pu L., Piorkowski J., Hankel A., Huo Y.,Gaspar T., Richter U., Hindricks G., Piorkowski C. Effect of concomitant Renal DeNervation and cardiac ablation on Atrial Fibrillation recurrence – RDN+AF study. J Cardiovasc Electrophysiol. 2023;34(1):44–53. doi: 10.1111/jce.15714.Kirstein B., Tomala J., Mayer J., Ulbrich S., Wagner M., Pu L., Piorkowski J., Hankel A., Huo Y.,Gaspar T., Richter U., Hindricks G., Piorkowski C. Effect of concomitant Renal DeNervation and cardiac ablation on Atrial Fibrillation recurrence – RDN+AF study. J Cardiovasc Electrophysiol. 2023;34(1):44–53. doi: 10.1111/jce.15714.

The authors declare that there are no conflicts of interest present.